Non-Small Cell Lung Cancer

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).

Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space.

Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year.

Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, details exciting findings from the EMPOWER-Lung 1 trial regarding cemiplimab and patients with non–small cell lung cancer (NSCLC).

Ticiana Leal, MD, associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the latest advances in perioperative non–small cell lung cancer (NSCLC) treatment.

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

Measures of systemic inflammation used for the liver, including C-reactive protein-albumin ratio and modified Glasgow prognostic score, demonstrated prognostic value in non–small cell lung cancer (NSCLC).

In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.

Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.

The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.

This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.

The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.

A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.

David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.

New therapies to treat EGFR-mutated non–small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitors (TKIs) are needed to address EGFR TKI resistance after osimertinib.

Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease recurrence.

Jason Porter, MD, provides concluding insights on the LAURA phase 3 trial, CHRYSALIS-2 study, TROPION-Lung05 trial, and CheckMate 9LA study, along with other notable findings from the ASCO 2024 conference.

Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.

Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.

For this analysis, investigators were interested in patient non–small cell lung cancer (NSCLC)–related outcomes from antibiotic administration before immunotherapy alone or immunotherapy and chemotherapy.

A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.

Jason Porter, MD, analyzes critical insights from the 2024 ASCO Annual Meeting presentation on progression-free survival data from the LAURA phase 3 trial, which evaluated osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer who did not progress after definitive chemoradiotherapy.

In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.